Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Among more than 200 BAP1-mutant families affected by the “BAP1 cancer syndrome,” nearly all individuals inheriting a BAP1 mutant allele developed one or more malignancies during their lifetime, mostly uveal and cutaneous melanoma, mesothelioma, and clear-cell renal cell carcinoma. These cancer types are also those that, when they occur sporadically, are more likely to carry somatic biallelic BAP1 mutations. Mechanistic studies revealed that the tumor suppressor function of BAP1 is linked to its dual activity in the nucleus, where it is implicated in a variety of processes including DNA repair and transcription, and in the cytoplasm, where it regulates cell death and mitochondrial metabolism. BAP1 activity in tumor suppression is cell type– and context-dependent. BAP1 has emerged as a critical tumor suppressor across multiple cancer types, predisposing to tumor development when mutated in the germline as well as somatically. Moreover, BAP1 has emerged as a key regulator of gene–environment interaction. This article is highlighted in the In This Issue feature, p. 1079
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As reported by Bononi et al., BAP1 regulates ER-to-mitochondria calcium (Ca2+) release; thus, mutations in BAP1 lead to the intracellular Ca2+ reduction required for the regulation of OXPHOS enzymes, resulting in an impairment of mitochondrial respiration and a switch toward glycolysis [139,140].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, some malignancies in germline BAP1 mutation carriers, especially mesotheliomas, are much less aggressive, even if the exact mechanism is not completely understood [139].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462 · cited 4×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundInfluentialGerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208 · cited 1×
“Following VHL inactivation, which is the signature and initiating event in ccRCC (85, 120, 121), a mutation of the second copy of BAP1 or PBRM1 likely leads to tumors of different grade and prognosis (19).”
BackgroundExome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123 · cited 1×
“PBRM1, which encodes a switching defective/sucrose nonfermenting (SWI/ SNF) nucleosome remodeling complex protein (BAF180), is inactivated in approximately 50% of ccRCC (20, 116).”
BackgroundGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 5×
“In 2011, Carbone’s team reported that germline BAP1 mutations predisposed to mesothelioma and uveal melanoma (14), the BAP1 cancer syndrome (6).”
BackgroundInfluentialSelf-citationBAP1 links metabolic regulation of ferroptosis to tumour suppression
Zhang, Y., Shi, J., Liu, X., Feng, L., Gong, Z., Koppula, P., Sirohi, K., Li, X., Wei, Y., Lee, H., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0178-0 · Cited by 1,013 · cited 3×
“SLC7A11 imports extracellular cystine, which is subsequently converted to cysteine in cells; cysteine is a rate-limiting precursor for glutathione (GSH) biosynthesis; GSH is used as a cofactor by glutathione peroxidase 4 to reduce lipid reactive oxygen species (ROS) to lipid alcohols; overproduction of lipid ROS in ce…”
BackgroundBAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959 · cited 23×
“In a study of 176 ccRCC at The University of Texas Southwestern (UTSW), where both IHC and DNA sequencing were performed, IHC results were interpretable in 175 tumors (20).”
BackgroundMethodInfluentialBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018) · Cancer Communications · doi:10.1186/s40880-018-0288-x · Cited by 915 · cited 1×
“Among these genes, SLC7A11 (encoding the Solute Carrier Family 7 Member 11), an antiporter that imports cystine and exports glutamate (35), was repressed by BAP1.”
BackgroundGermline mutations in BAP1 predispose to melanocytic tumors
Wiesner, T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.910 · Cited by 725 · cited 2×
“Once these independent studies were published (14, 16), the authors of these articles realized that multiple individuals in mesothelioma families L and W carried MBAITs and vice versa that multiple cases of mesothelioma had occurred in the families in which MBAITs had been discovered by dermatologists, thus confirming…”
BackgroundJensen, D. E., Proctor, M., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201861 · Cited by 723
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717 · cited 1×
“Initial studies underestimated the frequency of BAP1 mutations in mesothelioma as 22% to 23% (14, 77).”
BackgroundIntegrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Self-citationCarbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3459 · Cited by 590 · cited 5×
“1), including HCF1, YY1, OGT, KDM1B, and FOXK1 and 2 (6).”
BackgroundInfluentialVillani, A., Shore, A., Wasserman, J. D., Stephens, D., Kim, R. H., Druker, H., Gallinger, B., Naumer, A., Kohlmann, W., Novokmet, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30249-2 · Cited by 546 · cited 1×
“Instead, they should be screened preferentially using sonography and MRI (8) according to the same guidelines used for patients affected by the Li-Fraumeni cancer syndrome (73).”
MethodTiming the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Mitchell, T. J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J. H. R., O’Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.020 · Cited by 513 · cited 2×
“Following VHL inactivation, which is the signature and initiating event in ccRCC (85, 120, 121), a mutation of the second copy of BAP1 or PBRM1 likely leads to tumors of different grade and prognosis (19).”
BackgroundMandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511 · cited 1×
“A potential clinical interest of BAP1 NGS analysis is the identification of germline mutations not predicted by the clinical guidelines, as in those identified in mesothelioma by a large universal sequencing study conducted in more than 1,000 cases (86).”
BackgroundMalkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M., Nudleman, E., Aaberg, T. M., Altaweel, M. M., Bardenstein, D. S., Finger, P. T., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.017 · Cited by 506
Abdel-Rahman, M. H., Pilarski, R., Cebulla, C. M., Massengill, J. B., Christopher, B. N., Boru, G., Hovland, P., & Davidorf, F. H. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100156 · Cited by 487
Kapur, P., Peña-Llopis, S., Christie, A., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X.-J., & Brugarolas, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70584-3 · Cited by 471 · cited 2×
“Indeed, BAP1and PBRM1-deficient tumors differ not only in grade and prognosis, but also in gene expression (20, 119), and the mouse models show ccRCCs that are histologically quite different.”
BackgroundMutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450 · cited 1×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundBAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Bononi, A., Giorgi, C., Patergnani, S., Larson, D., Verbruggen, K., Tanji, M., Pellegrini, L., Signorato, V., Olivetto, F., Pastorino, S., et al. (2017) · Nature · doi:10.1038/nature22798 · Cited by 401 · cited 8×
“At times, however, a mutated, biologically inactive BAP1 (4) can accumulate in the cytoplasm where it forms amyloid (87), and it may produce cytoplasmic staining without accompanying nuclear staining (Fig.”
BackgroundInfluentialTumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Yu, H., Pak, H., Hammond-Martel, I., Ghram, M., Rodrigue, A., Daou, S., Barbour, H., Corbeil, L., Hébert, J., Drobetsky, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309085110 · Cited by 383 · cited 3×
“BAP1 promotes double-strand DNA repair by homologous recombination (HR), a key process to reduce genetic damage and prevent cancer (31, 32).”
BackgroundLoss of BAP1 function leads to EZH2-dependent transformation
LaFave, L. M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3947 · Cited by 381 · cited 4×
“Thus, the role of EZH2 inhibitors in BAP1-deficient cancers remains unclear, and the results of a clinical trial on tazemetostat in mesothelioma that has been completed are being evaluated (ref.”
BackgroundInfluentialMesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335 · cited 10×
“Adding to this puzzle, in sporadic mesotheliomas acquired biallelic BAP1 mutations are frequent, yet these mesotheliomas are not associated with significantly improved survival (8).”
BackgroundMethodInfluentialHigh Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Nasu, M., Emi, M., Pastorino, S., Tanji, M., Powers, A., Luk, H., Baumann, F., Zhang, Y.-A., Gazdar, A., Kanodia, S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000471 · Cited by 326 · cited 6×
“A subsequent study using a comprehensive integrated genomic approach that included Sanger sequencing, multiplex ligation–dependent probe amplification (MLPA), copy-number analysis, and cDNA sequencing, combined with IHC and DNA methylation analyses in mesothelioma biopsies, found that >60% carried biallelic somatic BA…”
BackgroundMethodInfluentialBAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Carbone, M., Ferris, L. K., Baumann, F., Napolitano, A., Lum, C. A., Flores, E. G., Gaudino, G., Powers, A., Bryant-Greenwood, P., Krausz, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-179 · Cited by 323 · cited 3×
“Numerous studies have now confirmed and expanded on the direct link of BAP1 germline mutations to a cancer syndrome characterized by a predisposition to mesothelioma (45–49), uveal melanoma (43), and less frequently cutaneous melanoma (50), as well as ccRCC (20, 44, 51, 52), which are the core cancer types in the BAP1…”
BackgroundGuo, G., Chmielecki, J., Goparaju, C., Heguy, A., Dolgalev, I., Carbone, M., Seepo, S., Meyerson, M., & Pass, H. I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1008 · Cited by 321
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
Brugarolas, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2003 · Cited by 306 · cited 3×
“Following VHL inactivation, which is the signature and initiating event in ccRCC (85, 120, 121), a mutation of the second copy of BAP1 or PBRM1 likely leads to tumors of different grade and prognosis (19).”
BackgroundRuan, H.-B., Han, X., Li, M.-D., Singh, J. P., Qian, K., Azarhoush, S., Zhao, L., Bennett, A. M., Samuel, V. T., Wu, J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.006 · Cited by 296 · cited 2×
“Furthermore, through the O-GlcNAc transferase/HCF1 complex, BAP1 regulates gluconeogenesis by modulating the stability of the transcriptional coactivator PGC1α (42).”
BackgroundHistone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Landreville, S., Agapova, O. A., Matatall, K. A., Kneass, Z. T., Onken, M. D., Lee, R. S., Bowcock, A. M., & Harbour, J. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0946 · Cited by 289 · cited 3×
“Histone deacetylases (HDAC), including class I HDAC1 and HDAC2, are epigenetic regulators of gene expression, which can be dysregulated in cancer, and have been proposed as targets by using specific inhibitors such as suberoylanilide hydroxamic acid (SAHA) or vorinostat for mesothelioma (132) and uveal melanoma (133)…”
BackgroundGermline BAP1 Mutations Predispose to Renal Cell Carcinomas
Popova, T., Hebert, L., Jacquemin, V., Gad, S., Caux-Moncoutier, V., Dubois-d’Enghien, C., Richaudeau, B., Renaudin, X., Sellers, J., Nicolas, A., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.012 · Cited by 279 · cited 1×
“Numerous studies have now confirmed and expanded on the direct link of BAP1 germline mutations to a cancer syndrome characterized by a predisposition to mesothelioma (45–49), uveal melanoma (43), and less frequently cutaneous melanoma (50), as well as ccRCC (20, 44, 51, 52), which are the core cancer types in the BAP1…”
BackgroundA High-Density Map for Navigating the Human Polycomb Complexome
Hauri, S., Comoglio, F., Seimiya, M., Gerstung, M., Glatter, T., Hansen, K., Aebersold, R., Paro, R., Gstaiger, M., & Beisel, C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.096 · Cited by 279
The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1
Machida, Y. J., Machida, Y., Vashisht, A. A., Wohlschlegel, J. A., & Dutta, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046755 · Cited by 274 · cited 9×
“It has been proposed that BAP1 may modulate cell proliferation by deubiquitylating the transcriptional regulator HCF1 (23, 25).”
BackgroundInfluentialYu, H., Mashtalir, N., Daou, S., Hammond-Martel, I., Ross, J., Sui, G., Hart, G. W., Rauscher, F. J., Drobetsky, E., Milot, E., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00396-10 · Cited by 270 · cited 2×
“BAP1 is found in a ternary complex with HCF1 and the transcription factor YY1 and activates YY1-regulated genes in a DUB-dependent manner (24).”
BackgroundGenetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R., & Carbone, M. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04013-7 · Cited by 266 · cited 1×
“August 2020 CANCER DISCOVERY | 1105 across multiple generations (9, 10).”
BackgroundDriver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes
Decatur, C. L., Ong, E., Garg, N., Anbunathan, H., Bowcock, A. M., Field, M. G., & Harbour, J. W. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0903 · Cited by 256 · cited 4×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundMethodInfluentialNjauw, C.-N. J., Kim, I., Piris, A., Gabree, M., Taylor, M., Lane, A. M., DeAngelis, M. M., Gragoudas, E., Duncan, L. M., & Tsao, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035295 · Cited by 254
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Baumann, F., Flores, E., Napolitano, A., Kanodia, S., Taioli, E., Pass, H., Yang, H., & Carbone, M. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu227 · Cited by 254 · cited 7×
“Survival data combine results from references: (54, 67, 99).”
BackgroundInfluentialA mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Carbone, M., Emri, S., Dogan, A. U., Steele, I., Tuncer, M., Pass, H. I., & Baris, Y. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2068 · Cited by 253 · cited 5×
“families with multiple cases of mesothelioma, and proposed the existence of a mesothelioma-predisposing gene (9).”
BackgroundInfluentialComprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Walpole, S., Pritchard, A. L., Cebulla, C. M., Pilarski, R., Stautberg, M., Davidorf, F. H., de la Fouchardière, A., Cabaret, O., Golmard, L., Stoppa-Lyonnet, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy171 · Cited by 253 · cited 2×
“Some of the BAP1-associated cancers, such as mesotheliomas and skin melanomas, are strongly linked to environmental carcinogens (60), suggesting GxE interaction in some instances (8, 18, 55, 61).”
BackgroundPTEN Counteracts FBXL2 to Promote IP3R3- and Ca2+-Mediated Apoptosis Limiting Tumour Growth
Kuchay, S., Giorgi, C., Simoneschi, D., Pagan, J., Missiroli, S., Saraf, A., Florens, L., Washburn, M. P., Collazo-Lorduy, A., Castillo-Martin, M., et al. (2017) · Nature · doi:10.1038/nature22965 · Cited by 251
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Panou, V., Gadiraju, M., Wolin, A., Weipert, C. M., Skarda, E., Husain, A. N., Patel, J. D., Rose, B., Zhang, S. R., Weatherly, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5204 · Cited by 229 · cited 1×
“An analysis conducted at the University of Chicago on the germline DNA of 198 patients with mesothelioma using targeted capture and NGS of 85 cancer susceptibility genes revealed that 12% of patients within this cohort carried pathogenic germline mutations; BAP1 was the most commonly mutated gene (47).”
MethodComprehensive review of BAP1 tumor predisposition syndrome with report of two new cases
Rai, K., Pilarski, R., Cebulla, C. M., & Abdel‐Rahman, M. H. (2016) · Clinical Genetics · doi:10.1111/cge.12630 · Cited by 228
BRCA1-Associated Protein 1 Interferes with BRCA1/BARD1 RING Heterodimer Activity
Nishikawa, H., Wu, W., Koike, A., Kojima, R., Gomi, H., Fukuda, M., & Ohta, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3355 · Cited by 221 · cited 7×
“However, a recent interactome study based on an affi nity purifi cation mass spectrometry approach identifi ed neither BRCA1 nor BARD1 in association with BAP1 and the human polycomb complex ( 3 ).”
BackgroundInfluentialGermline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
Ismail, I. H., Davidson, R., Gagné, J.-P., Xu, Z. Z., Poirier, G. G., & Hendzel, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3109 · Cited by 215 · cited 2×
“BAP1 promotes double-strand DNA repair by homologous recombination (HR), a key process to reduce genetic damage and prevent cancer (31, 32).”
BackgroundKrug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D., Öhman, R., Plummer, R., Eberhardt, W. E. E., Fukuoka, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70056-2 · Cited by 215 · cited 1×
“However, patients with mesothelioma—not selected for BAP1 status—treated in the second or third line in the randomized phase III VANTAGE-014 trial with vorinostat did not show improved survival (135).”
BackgroundMisaghi, S., Ottosen, S., Izrael-Tomasevic, A., Arnott, D., Lamkanfi, M., Lee, J., Liu, J., O'Rourke, K., Dixit, V. M., & Wilson, A. C. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01517-08 · Cited by 212 · cited 8×
“It has been proposed that BAP1 may modulate cell proliferation by deubiquitylating the transcriptional regulator HCF1 (23, 25).”
BackgroundInfluentialErionite exposure in North Dakota and Turkish villages with mesothelioma
Carbone, M., Baris, Y. I., Bertino, P., Brass, B., Comertpay, S., Dogan, A. U., Gaudino, G., Jube, S., Kanodia, S., Partridge, C. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105887108 · Cited by 211 · cited 1×
“In Cappadocia, the population was exposed to erionite (11), a carcinogenic mineral fiber similar to asbestos (12).”
BackgroundMashtalir, N., Daou, S., Barbour, H., Sen, N. N., Gagnon, J., Hammond-Martel, I., Dar, H. H., Therrien, M., & Affar, E. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.002 · Cited by 195 · cited 1×
“In addition, chromothripsis has been observed in ccRCC where it results in a t(3;5) derivative chromosome, leaving a wild-type chromosome 3 and two copies of wild-type chromosome 5 (85).”
BackgroundPunctuated evolution of canonical genomic aberrations in uveal melanoma
Field, M. G., Durante, M. A., Anbunathan, H., Cai, L. Z., Decatur, C. L., Bowcock, A. M., Kurtenbach, S., & Harbour, J. W. (2018) · Nature Communications · doi:10.1038/s41467-017-02428-w · Cited by 195 · cited 5×
“This figure represents a synopsis of published data (68, 101, 178).”
BackgroundMethodInfluentialAcquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
Pratcorona, M., Abbas, S., Sanders, M. A., Koenders, J. E., Kavelaars, F. G., Erpelinck-Verschueren, C. A. J., Zeilemakers, A., Lowenberg, B., & Valk, P. J. M. (2012) · Haematologica · doi:10.3324/haematol.2011.051532 · Cited by 191 · cited 1×
“BAP1 forms two mutually exclusive complexes with the product of ASXL1, which is frequently mutated in myeloid leukemia (29), and of ASXL2.”
BackgroundCarlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., Knezevic, A., Patil, S., Ceyhan-Birsoy, O., Huang, K.-C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1986 · Cited by 187
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
Shankar, G. M., Abedalthagafi, M., Vaubel, R. A., Merrill, P. H., Nayyar, N., Gill, C. M., Brewster, R., Bi, W. L., Agarwalla, P. K., Thorner, A. R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now235 · Cited by 184 · cited 1×
“Less frequently associated cancers include cholangiocarcinoma (58), meningioma (59), and others (ref.”
BackgroundPanda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181 · cited 1×
“What drives the inflammation in BAP1-deficient ccRCCs is unclear, but a recent study found a link between BAP1 loss and the expression of endogenous retroviruses (142).”
BackgroundModeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Gu, Y.-F., Cohn, S., Christie, A., McKenzie, T., Wolff, N., Do, Q. N., Madhuranthakam, A. J., Pedrosa, I., Wang, T., Dey, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0292 · Cited by 176 · cited 3×
“To determine whether BAP1 and PBRM1 directly affect tumor grade, mice were generated with targeted inactivation of Bap1 or Pbrm1 in the kidney using the same Cre driver (117).”
BackgroundMethodResultBAP1 mutations in high-grade meningioma: implications for patient care
Shankar, G. M., & Santagata, S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox094 · Cited by 174
High frequency of de novo mutations in Li–Fraumeni syndrome
Gonzalez, K. D., Buzin, C. H., Noltner, K. A., Gu, D., Li, W., Malkin, D., & Sommer, S. S. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.058958 · Cited by 170
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma
Matatall, K. A., Agapova, O. A., Onken, M. D., Worley, L. A., Bowcock, A. M., & Harbour, J. W. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-371 · Cited by 168 · cited 1×
“Loss of BAP1 abrogates this differentiation switch in development that parallels phenotypic and transcriptomic alterations observed in association with BAP1 mutation in uveal melanoma (114).”
BackgroundWang, T., Lu, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1246 · Cited by 168 · cited 3×
“By subtracting the tumorgraft transcriptome from the patient tumor transcriptome, Wang and colleagues were able to empirically define the TME in RCC (141).”
BackgroundMethodApplication of immunohistochemistry in diagnosis and management of malignant mesothelioma
Chapel, D. B., Schulte, J. J., Husain, A. N., & Krausz, T. N. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.29 · Cited by 168 · cited 2×
“This IHC test has been utilized extensively (more than 3,000 RCCs) at UTSW (94–98) and there is a Clinical Laboratory Improvement Amendments (CLIA)– certified IHC test being implemented in routine clinical practice (7, 8, 78, 90, 91).”
BackgroundMethodNapolitano, A., Pellegrini, L., Dey, A., Larson, D., Tanji, M., Flores, E. G., Kendrick, B., Lapid, D., Powers, A., Kanodia, S., et al. (2016) · Oncogene · doi:10.1038/onc.2015.243 · Cited by 161 · cited 4×
“BAP1 mutations may influence the response to immunotherapy by increasing the propensity to chromothripsis, by deregulating the expression of genes that modulate immune checkpoints, and by promoting a proinflammatory tumor microenvironment (62, 141, 145).”
BackgroundInfluentialJoseph, R. W., Kapur, P., Serie, D. J., Eckel‐Passow, J. E., Parasramka, M., Ho, T., Cheville, J. C., Frenkel, E., Rakheja, D., Brugarolas, J., et al. (2014) · Cancer · doi:10.1002/cncr.28521 · Cited by 161 · cited 2×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundAsbestos is not just asbestos: an unrecognised health hazard
Baumann, F., Ambrosi, J.-P., & Carbone, M. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70257-2 · Cited by 158 · cited 1×
“In Cappadocia, the population was exposed to erionite (11), a carcinogenic mineral fiber similar to asbestos (12).”
BackgroundHassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., Gadiraju, M., Panou, V., Gao, S., Mian, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821510116 · Cited by 158 · cited 3×
“The difference in survival is quite significant, with median survival of 5 to 7 years for mesothelioma developing in carriers of heterozygous BAP1 mutations compared with 1-year median survival in sporadic mesotheliomas, cancers characteristically resistant to therapy (54, 67, 99).”
BackgroundA Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Farley, M. N., Schmidt, L. S., Mester, J. L., Peña-Llopis, S., Pavia-Jimenez, A., Christie, A., Vocke, C. D., Ricketts, C. J., Peterson, J., Middelton, L., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0111 · Cited by 151 · cited 2×
“Numerous studies have now confirmed and expanded on the direct link of BAP1 germline mutations to a cancer syndrome characterized by a predisposition to mesothelioma (45–49), uveal melanoma (43), and less frequently cutaneous melanoma (50), as well as ccRCC (20, 44, 51, 52), which are the core cancer types in the BAP1…”
BackgroundYoshikawa, Y., Emi, M., Hashimoto-Tamaoki, T., Ohmuraya, M., Sato, A., Tsujimura, T., Hasegawa, S., Nakano, T., Nasu, M., Pastorino, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612074113 · Cited by 149 · cited 6×
“(SETD2, PBRM1, and SMARCC1), alternating with segments showing oscillating copy-number changes along the 3p21 chromosome, findings suggestive of chromothripsis (79).”
BackgroundMethodInfluentialBap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis
Wang, S.-S., Gu, Y.-F., Wolff, N., Stefanius, K., Christie, A., Dey, A., Hammer, R. E., Xie, X.-J., Rakheja, D., Pedrosa, I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414789111 · Cited by 147 · cited 1×
“Inactivation of Bap1 or Pbrm1, along with Vhl, which is uniformly inactivated in ccRCC, led to the development of ccRCC (117, 118).”
BackgroundBAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Shrestha, R., Nabavi, N., Lin, Y.-Y., Mo, F., Anderson, S., Volik, S., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0620-3 · Cited by 147 · cited 1×
“This evidence makes BAP1 a candidate predictive biomarker for immunotherapy in peritoneal mesothelioma (143) and possibly also in pleural mesothelioma (144).”
BackgroundDaou, S., Hammond-Martel, I., Mashtalir, N., Barbour, H., Gagnon, J., Iannantuono, N. G., Nkwe, N. S., Motorina, A., Pak, H., Yu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.661553 · Cited by 146 · cited 4×
“BAP1 0 A B 5 10 BAP1 ASXL1/2 Differentiation Loss of cell identity Metastasis BAP1 loss in UVM H2AK119ub H3K37me3 H3K37Ac H2AK119ub H3K37me3BAP1 H3K37Ac Years since treatment SF3B1 (25”
BackgroundInfluentialThe prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma
Singhi, A. D., Krasinskas, A. M., Choudry, H. A., Bartlett, D. L., Pingpank, J. F., Zeh, H. J., Luvison, A., Fuhrer, K., Bahary, N., Seethala, R. R., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.121 · Cited by 146 · cited 1×
“Mesotheliomas with acquired BAP1 mutations are mostly of the epithelial type and may have a slightly improved prognosis of a few months compared with mesotheliomas of similar histologic type with wild-type BAP1 (102–104); however, some studies did not support this finding (105).”
ResultGermline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144 · cited 2×
“BAP1’s role in increasing susceptibility to asbestos, UV light, and ionizing radiation has been established in primary human fibroblasts and mesothelial cells in culture (4), and it has been demonstrated in mice exposed to asbestos (62, 63).”
BackgroundStabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis
Lee, H.-S., Lee, S.-A., Hur, S.-K., Seo, J., & Kwon, J. (2014) · Nature Communications · doi:10.1038/ncomms6128 · Cited by 144 · cited 2×
“BAP1 interacts with and deubiquitylates INO80, playing a critical role in stabilizing and targeting the INO80 chromatin-remodeling complex to the replication forks (21).”
BackgroundPastorino, S., Yoshikawa, Y., Pass, H. I., Emi, M., Nasu, M., Pagano, I., Takinishi, Y., Yamamoto, R., Minaai, M., Hashimoto-Tamaoki, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0352 · Cited by 143 · cited 6×
“Survival data combine results from references: (54, 67, 99).”
BackgroundInfluentialClear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
Joseph, R. W., Kapur, P., Serie, D. J., Parasramka, M., Ho, T. H., Cheville, J. C., Frenkel, E., Parker, A. S., & Brugarolas, J. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.07.113 · Cited by 142 · cited 3×
“ccRCC can be classified into 4 subtypes according to BAP1 and PBRM1 status, and these subtypes are associated with differential kidney cancer–specific survival in patients (20, 98).”
BackgroundContribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome
Renaux‐Petel, M., Charbonnier, F., Théry, J., Fermey, P., Lienard, G., Bou, J., Coutant, S., Vézain, M., Kasper, E., Fourneaux, S., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104976 · Cited by 140
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
Carlo, M. I., Hakimi, A. A., Stewart, G. D., Bratslavsky, G., Brugarolas, J., Chen, Y., Linehan, W. M., Maher, E. R., Merino, M. J., Offit, K., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.015 · Cited by 136 · cited 1×
“In addition, a large study in more than 100 cases of metastatic RCC demonstrated that BAP1 mutational status did not correlate with clinical benefit upon rapalog therapy (130), despite the significantly higher aggressiveness of RCC in carriers of BAP1 mutations (131).”
BackgroundGermline BAP1 mutations induce a Warburg effect
Bononi, A., Yang, H., Giorgi, C., Patergnani, S., Pellegrini, L., Su, M., Xie, G., Signorato, V., Pastorino, S., Morris, P., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.95 · Cited by 133
Self-citationClinical Characteristics of Uveal Melanoma in Patients With GermlineBAP1Mutations
Patel, M. M., Lane, A. M., DeAngelis, M. M., Mayne, K., Crabtree, M. M., Gragoudas, E. S., & Kim, I. K. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.1119 · Cited by 131 · cited 3×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundResultPrognostic parameters in uveal melanoma and their association with BAP1 expression
van Essen, T. H., van Pelt, S. I., Versluis, M., Bronkhorst, I. H. G., van Duinen, S. G., Marinkovic, M., Kroes, W. G. M., Ruivenkamp, C. A. L., Shukla, S., de Klein, A., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305047 · Cited by 129
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Mansfield, A. S., Peikert, T., Smadbeck, J. B., Udell, J. B. M., Garcia-Rivera, E., Elsbernd, L., Erskine, C. L., Van Keulen, V. P., Kosari, F., Murphy, S. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.001 · Cited by 129 · cited 1×
“The occurrence of chromothripsis in mesothelioma may be favored by BAP1 inactivation (79), and it has been confirmed by mate-pair sequencing (MPseq) analyses (83) and by WES (84).”
BackgroundMcGregor, S. M., Dunning, R., Hyjek, E. M., Vigneswaran, W. T., Husain, A. N., & Krausz, T. N. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.06.024 · Cited by 127 · cited 1×
“This IHC test has been utilized extensively (more than 3,000 RCCs) at UTSW (94–98) and there is a Clinical Laboratory Improvement Amendments (CLIA)– certified IHC test being implemented in routine clinical practice (7, 8, 78, 90, 91).”
MethodKrug, L. M., Curley, T., Schwartz, L. B., Richardson, S., Marks, P. A., Chiao, J. H., & Kelly, W. K. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.003 · Cited by 120 · cited 1×
“Histone deacetylases (HDAC), including class I HDAC1 and HDAC2, are epigenetic regulators of gene expression, which can be dysregulated in cancer, and have been proposed as targets by using specific inhibitors such as suberoylanilide hydroxamic acid (SAHA) or vorinostat for mesothelioma (132) and uveal melanoma (133)…”
BackgroundA cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma
Wadt, K., Choi, J., Chung, J., Kiilgaard, J., Heegaard, S., Drzewiecki, K. T., Trent, J. M., Hewitt, S. M., Hayward, N. K., Gerdes, A., et al. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12006 · Cited by 116
Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1
He, M. X., Chaurushiya, M. S., Webster, J. D., Kummerfeld, S., Reja, R., Chaudhuri, S., Chen, Y., Modrusan, Z. D., Haley, B., Dugger, D. L., et al. (2019) · Science · doi:10.1126/science.aav4902 · Cited by 114 · cited 1×
“By engineering a knock-in mouse model expressing the catalytically inactive C91A Bap1 mutant, He and colleagues showed that the loss of function of BAP1 has a proapoptotic effect in mouse embryonic stem cells, fibroblasts, liver, and pancreas, but not in melanocytes and mesothelial cells, the cells that give rise to t…”
BackgroundPilarski, R., Cebulla, C. M., Massengill, J. B., Rai, K., Rich, T., Strong, L., McGillivray, B., Asrat, M., Davidorf, F. H., & Abdel‐Rahman, M. H. (2014) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22129 · Cited by 112
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti, L., Peikert, T., Robinson, B. W. S., Scherpereel, A., Tsao, A. S., de Perrot, M., Woodard, G. A., Jablons, D. M., Wiens, J., Hirsch, F. R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.011 · Cited by 112
Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm
Peña‐Llopis, S., Christie, A. L., Xie, X.-J., & Brugarolas, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0360 · Cited by 110 · cited 16×
“100 WT PBRM1 BAP1 PBRM1/BAP1 80 60 40 20 0 0 5 Vhl/Bap1Vhl/Pbrm1 Kidney cancer aggressiveness: 10 15 20 Time (years since surgery) WT PBRM1 BAP1 PBRM1/BAP1 K id ne y ca nc er –s pe ci fic s ur vi va l r at e (% ) Cancer Research. on January 7, 2022.”
BackgroundInfluentialOhar, J. A., Cheung, M., Talarchek, J., Howard, S. E., Howard, T. D., Hesdorffer, M., Peng, H., Rauscher, F. J., & Testa, J. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0295 · Cited by 107
Andrici, J., Sheen, A., Sioson, L., Wardell, K. L., Clarkson, A., Watson, N., Ahadi, M. S., Farzin, M., Toon, C. W., & Gill, A. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.87 · Cited by 107
Gerlinger, M., Santos, C. R., Spencer‐Dene, B., Martinez, P., Endesfelder, D., Burrell, R. A., Vetter, M., Jiang, M., Saunders, R. E., Kelly, G., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4006 · Cited by 106 · cited 1×
“Following VHL inactivation, which is the signature and initiating event in ccRCC (85, 120, 121), a mutation of the second copy of BAP1 or PBRM1 likely leads to tumors of different grade and prognosis (19).”
Backgroundvan de Nes, J. A. P., Schillinger, J., Kreis, S. H., Metz, C. H. D., Hager, T., Lohmann, D. R., & Zeschnigk, M. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000645 · Cited by 106 · cited 2×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundKadariya, Y., Cheung, M., Xu, J., Pei, J., Sementino, E., Menges, C. W., Cai, K. Q., Rauscher, F. J., Klein-Szanto, A. J., & Testa, J. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3371 · Cited by 105 · cited 1×
“However, the spontaneous development of mesotheliomas in Bap1+/− mice not exposed to asbestos (65, 66), and the development of multiple cancer types in carriers of BAP1 mutations (Fig.”
BackgroundHaugh, A. M., Njauw, C.-N., Bubley, J. A., Verzì, A. E., Zhang, B., Kudalkar, E., VandenBoom, T., Walton, K., Swick, B. L., Kumar, R., et al. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.2330 · Cited by 105 · cited 2×
“Some of the BAP1-associated cancers, such as mesotheliomas and skin melanomas, are strongly linked to environmental carcinogens (60), suggesting GxE interaction in some instances (8, 18, 55, 61).”
BackgroundToward an Improved Definition of the Tumor Spectrum Associated With BAP1 Germline Mutations
Wiesner, T., Fried, I., Ulz, P., Stacher, E., Popper, H., Murali, R., Kutzner, H., Lax, S., Smolle-Jüttner, F., Geigl, J. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2965 · Cited by 101
Germline BAP1 mutations predispose also to multiple basal cell carcinomas
de la Fouchardière, A., Cabaret, O., Savin, L., Combemale, P., Schvartz, H., Penet, C., Bonadona, V., Soufir, N., & Bressac‐de Paillerets, B. (2015) · Clinical Genetics · doi:10.1111/cge.12472 · Cited by 99
BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response
Dai, F., Lee, H., Zhang, Y., Zhuang, L., Yao, H., Xi, Y., Xiao, Z.-D., You, M. J., Li, W., Su, X., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619588114 · Cited by 94 · cited 1×
“The transcriptional repression of ATF3 and CHOP is dependent upon the deubiquitinylation of H2A (at K119) by BAP1 (37).”
BackgroundWadt, K. A. W., Aoude, L. G., Johansson, P., Solinas, A., Pritchard, A., Crainic, O., Andersen, M. T., Kiilgaard, J. F., Heegaard, S., Sunde, L., et al. (2015) · Clinical Genetics · doi:10.1111/cge.12501 · Cited by 92
Carbone, M., Flores, E. G., Emi, M., Johnson, T. A., Tsunoda, T., Behner, D., Hoffman, H., Hesdorffer, M., Nasu, M., Napolitano, A., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005633 · Cited by 89 · cited 2×
“2B), including tumor types that have not been associated with known carcinogens (53, 67), suggests that BAP1 mutations also drive tumor growth independently of genotoxic stress, perhaps by favoring the accumulation of age-related DNA damage.”
BackgroundJi, Z., Mohammed, H., Webber, A., Ridsdale, J., Han, N., Carroll, J. S., & Sharrocks, A. D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku274 · Cited by 88 · cited 1×
“BAP1 can also be recruited to the DNA via interaction with FOXK2, which promotes local histone deubiquitylation inducing changes in target gene activity (26).”
BackgroundFurther evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma
Cheung, M., Talarchek, J. N., Schindeler, K. L., Saraiva, E., Penney, L. S., Ludman, M. D., & Testa, J. R. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.05.018 · Cited by 88
Farquhar, N., Thornton, S., Coupland, S. E., Coulson, J. M., Sacco, J. J., Krishna, Y., Heimann, H., Taktak, A. F. G., Cebulla, C. M., Abdel‐Rahman, M. H., et al. (2017) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.86 · Cited by 87 · cited 2×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundKuznetsov, J. N., Aguero, T. H., Owens, D. A., Kurtenbach, S., Field, M. G., Durante, M. A., Rodriguez, D. A., King, M. L., & Harbour, J. W. (2019) · Science Advances · doi:10.1126/sciadv.aax1738 · Cited by 86 · cited 7×
“Thus, the role of EZH2 inhibitors in BAP1-deficient cancers remains unclear, and the results of a clinical trial on tazemetostat in mesothelioma that has been completed are being evaluated (ref.”
BackgroundInfluentialBAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
Arzt, L., Quehenberger, F., Halbwedl, I., Mairinger, T., & Popper, H. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9677-2 · Cited by 85
Okino, Y., Machida, Y., Frankland-Searby, S., & Machida, Y. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.609834 · Cited by 81 · cited 1×
“Moreover, BAP1 is part of a ternary complex bridging FOXK2 and HCF1 and represses FOXK2 target genes, an effect requiring BAP1 DUB activity but not the interaction with HCF1 binding (27).”
BackgroundCDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
Betti, M., Aspesi, A., Biasi, A., Casalone, E., Ferrante, D., Ogliara, P., Gironi, L. C., Giorgione, R., Farinelli, P., Grosso, F., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.011 · Cited by 78
Kapur, P., Christie, A. L., Raman, J. D., Then, M. T., Nuhn, P., Büchner, A., Bastian, P. J., Seitz, C., Shariat, S. F., Bensalah, K., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.09.041 · Cited by 77
Forest, F., Patoir, A., Col, P. D., Sulaiman, A., Camy, F., Laville, D., Bayle-Bleuez, S., Fournel, P., & Habougit, C. (2018) · Pathology · doi:10.1016/j.pathol.2018.05.002 · Cited by 76
Progress in the Management of Malignant Pleural Mesothelioma in 2017
McCambridge, A. J., Napolitano, A., Mansfield, A. S., Fennell, D. A., Sekido, Y., Nowak, A. K., Reungwetwattana, T., Mao, W., Pass, H. I., Carbone, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.021 · Cited by 75 · cited 1×
“The incorporation of the active metabolite of gemcitabine into DNA causes replication arrest and apoptosis, making this drug one of the most used chemotherapeutic agents against several cancers, including mesothelioma, for which it is approved as second-line treatment (125).”
BackgroundBAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations
Piris, A., Mihm, M. C., & Hoang, M. P. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.10.015 · Cited by 73 · cited 1×
“Currently, the detection of MBAITs allows dermatologists to identify potential carriers of germline BAP1 mutations, a diagnosis that is confirmed by germline DNA sequencing (8, 17, 18).”
BackgroundNeuCode Proteomics Reveals Bap1 Regulation of Metabolism
Baughman, J. M., Rose, C. M., Kolumam, G., Webster, J. D., Wilkerson, E. M., Merrill, A. E., Rhoads, T. W., Noubade, R., Katavolos, P., Lesch, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.096 · Cited by 73 · cited 1×
“The downregulation of mitochondrial proteins in the pancreas was accompanied by pancreatitis (41).”
BackgroundSelf-citationBetti, M., Casalone, E., Ferrante, D., Romanelli, A., Grosso, F., Guarrera, S., Righi, L., Vatrano, S., Pelosi, G., Libener, R., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22218 · Cited by 71
Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1
Daou, S., Barbour, H., Ahmed, O., Masclef, L., Baril, C., Sen Nkwe, N., Tchelougou, D., Uriarte, M., Bonneil, E., Ceccarelli, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06854-2 · Cited by 71 · cited 1×
“Furthermore, BAP1 deubiquitylates the deubiquitylase adaptor module DEUBAD of ASXL2, leading to its stabilization (30).”
BackgroundChau, C. H., van Doorn, R., van Poppelen, N. M., van der Stoep, N., Mensenkamp, A. R., Sijmons, R. H., van Paassen, B. W., van den Ouweland, A. M. W., Naus, N. C., van der Hout, A. H., et al. (2019) · Cancers · doi:10.3390/cancers11081114 · Cited by 69
Rathkey, D., Khanal, M., Murai, J., Zhang, J., Sengupta, M., Jiang, Q., Morrow, B., Evans, C. N., Chari, R., Fetsch, P., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.012 · Cited by 69 · cited 1×
“However, very recently Hassan and colleagues reported that BAP1 status does not determine sensitivity to PARP inhibitors in patient-derived mesothelioma cell lines (140).”
BackgroundModern Criteria to Establish Human Cancer Etiology
Carbone, M., Klein, G., Gruber, J., & Wong, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0255 · Cited by 68 · cited 1×
“Some of the BAP1-associated cancers, such as mesotheliomas and skin melanomas, are strongly linked to environmental carcinogens (60), suggesting GxE interaction in some instances (8, 18, 55, 61).”
BackgroundUveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status
Schoumacher, M., Corre, S. L., Houy, A., Mulugeta, E., Stern, M., Roman‐Roman, S., & Margueron, R. (2016) · Nature Medicine · doi:10.1038/nm.4098 · Cited by 67 · cited 1×
“However, this effect was not seen in neural crest–derived uveal melanoma cells (147).”
BackgroundParrotta, R., Okonska, A., Ronner, M., Weder, W., Stahel, R., Penengo, L., & Felley-Bosco, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.023 · Cited by 65 · cited 1×
“A BAP1 mutant by alternative splicing resulting in a 54-bp deletion increased sensitivity to the PARP inhibitor olaparib (138).”
BackgroundCarbone, M., Shimizu, D., Napolitano, A., Tanji, M., Pass, H. I., Yang, H., & Pastorino, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10653 · Cited by 64 · cited 1×
“Negative BAP1 nuclear staining is also helpful in the often difficult differential diagnosis between primary mesothelioma (most of them BAP1-negative) and metastatic lung carcinomas to the pleura, which instead are nearly always BAP1-positive (92, 93).”
BackgroundLuchini, C., Veronese, N., Yachida, S., Cheng, L., Nottegar, A., Stubbs, B., Solmi, M., Capelli, P., Pea, A., Barbareschi, M., et al. (2016) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22381 · Cited by 62
BAP1 regulates different mechanisms of cell death
Affar, E. B., & Carbone, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1206-5 · Cited by 62 · cited 1×
“It remains to be studied whether the two distinct types of programmed cell death linked to BAP1, apoptosis and ferroptosis, are controlled in a synchronized or an independent manner (36) and whether BAP1 regulates additional mechanisms of cell death.”
BackgroundKleihues, P., Ohgaki, H., & Hainaut, P. (2001) · Springer eBooks · doi:10.1007/978-3-642-56889-3_14 · Cited by 60
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Srinivasan, G., Sidhu, G. S., Williamson, E. A., Jaiswal, A. S., Najmunnisa, N., Wilcoxen, K., Jones, D., George, T. J., & Hromas, R. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3401-y · Cited by 60 · cited 1×
“Several studies proposed to test the efficacy of PARP inhibitors in mesothelioma, although patients were not selected for BAP1 status (136, 137).”
BackgroundSacco, J. J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., Darling, S., Denny, M., Urbé, S., Clague, M. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3765 · Cited by 59 · cited 1×
“Upon BAP1 loss, HDAC1 is increased and HDAC2 is reduced, an effect that was observed across several lung cancer and mesothelioma cell lines (134).”
BackgroundMcGregor, S. M., McElherne, J., Minor, A., Keller‐Ramey, J., Dunning, R., Husain, A. N., Vigneswaran, W. T., Fitzpatrick, C. A., & Krausz, T. N. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.09.026 · Cited by 58 · cited 1×
“This IHC test has been utilized extensively (more than 3,000 RCCs) at UTSW (94–98) and there is a Clinical Laboratory Improvement Amendments (CLIA)– certified IHC test being implemented in routine clinical practice (7, 8, 78, 90, 91).”
MethodComparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma
Ewens, K. G., Lalonde, E., Richards‐Yutz, J., Shields, C. L., & Ganguly, A. A. (2018) · BMC Cancer · doi:10.1186/s12885-018-5079-x · Cited by 58
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58 · cited 1×
“This evidence makes BAP1 a candidate predictive biomarker for immunotherapy in peritoneal mesothelioma (143) and possibly also in pleural mesothelioma (144).”
BackgroundBAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
Guazzelli, A., Meysami, P., Bakker, E., Demonacos, C., Giordano, A., Krstic-Demonacos, M., & Mutti, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020429 · Cited by 56 · cited 2×
“Similarly, mesothelioma cells expressing wild-type BAP1 were more sensitive to gemcitabine-induced apoptosis and cell-cycle derangement, compared with mesothelioma cells expressing nonfunctional BAP1 or silenced for BAP1 (128).”
BackgroundHo, T. H., Kapur, P., Joseph, R. W., Serie, D., Eckel‐Passow, J. E., Parasramka, M. A., Cheville, J. C., Wu, K. J., Frenkel, E. P., Rakheja, D., et al. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.10.014 · Cited by 55 · cited 1×
“A fourth tumor suppressor gene in the same 3p region, SETD2, is also mutated in ccRCC and is associated with poor prognosis (94).”
BackgroundA BAP1 Mutation in a Danish Family Predisposes to Uveal Melanoma and Other Cancers
Aoude, L. G., Wadt, K., Bojesen, A., Crüger, D., Borg, Å., Trent, J. M., Brown, K. M., Gerdes, A.-M., Jönsson, G., & Hayward, N. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072144 · Cited by 55
BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma
Turunen, J. A., Markkinen, S., Wilska, R., Saarinen, S., Raivio, V., Täll, M., Lehesjoki, A., & Kivelä, T. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.008 · Cited by 54
Ribeiro, C. S. M. F., Campelos, S., Moura, C. S., Machado, J. C., Justino, A., & Parente, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt135 · Cited by 53
Bhattacharya, S., Hanpude, P., & Maiti, T. K. (2015) · Scientific Reports · doi:10.1038/srep18462 · Cited by 49 · cited 1×
“At times, however, a mutated, biologically inactive BAP1 (4) can accumulate in the cytoplasm where it forms amyloid (87), and it may produce cytoplasmic staining without accompanying nuclear staining (Fig.”
BackgroundCombined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
Badhai, J., Pandey, G. K., Song, J.-Y., Krijgsman, O., Bhaskaran, R., Chandrasekaran, G., Kwon, M.-C., Bombardelli, L., Monkhorst, K., Grasso, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191257 · Cited by 49 · cited 3×
“Intriguingly, LOH for BAP1 is not always observed in tumors developing in mice carrying germline Bap1 mutations (62, 65).”
BackgroundCheung, M., Kadariya, Y., Talarchek, J., Pei, J., Ohar, J. A., Kayaleh, O. R., & Testa, J. R. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.011 · Cited by 48 · cited 1×
“Parallel studies reported evidence of GxE interaction in mice (63) and also in one BAP1-mutant family (64).”
BackgroundBAP1: role in carcinogenesis and clinical implications
Kobrinski, D. A., Yang, H., & Kittaneh, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.24 · Cited by 48
BAP1 hereditary cancer predisposition syndrome: a case report and review of literature
Klebe, S., Driml, J., Nasu, M., Pastorino, S., Zangiabadi, A., Henderson, D., & Carbone, M. (2015) · Biomarker Research · doi:10.1186/s40364-015-0040-5 · Cited by 46
Aaberg, T., Cook, R. W., Oelschlager, K. M., Maetzold, D. J., Rao, P. K., & Mason, J. O. (2014) · Clinical ophthalmology · doi:10.2147/opth.s70839 · Cited by 46
Loss of expression of BAP1 is very rare in non-small cell lung carcinoma
Andrici, J., Parkhill, T. R., Jung, J. J., Wardell, K. L., Verdonk, B., Singh, A., Sioson, L., Clarkson, A., Watson, N., Sheen, A., et al. (2016) · Pathology · doi:10.1016/j.pathol.2016.03.005 · Cited by 46 · cited 1×
“Negative BAP1 nuclear staining is also helpful in the often difficult differential diagnosis between primary mesothelioma (most of them BAP1-negative) and metastatic lung carcinomas to the pleura, which instead are nearly always BAP1-positive (92, 93).”
BackgroundAnalysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients
Cebulla, C. M., Binkley, E. M., Pilarski, R., Massengill, J. B., Rai, K., Liebner, D. A., Marino, M. J., Singh, A. D., & Abdel‐Rahman, M. H. (2015) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1010734 · Cited by 44
BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress
Lee, H.-S., Seo, H.-R., Lee, S.-A., Choi, S., Kang, D., & Kwon, J. (2019) · Biochemical Journal · doi:10.1042/bcj20190622 · Cited by 43 · cited 2×
“BAP1 stabilizes and recruits INO80 to replication forks, via the interaction with H2A-Ub, for efficient replication fork progression and DNA replication, thereby ensuring genome stability (21, 22).”
BackgroundThe Cappadocia mesothelioma epidemic: its influence in Turkey and abroad
Emri, S. A. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.04.06 · Cited by 40 · cited 1×
“However, mesothelioma was detected in some families, but not in others similarly exposed to erionite fibers (9, 13).”
BackgroundBorchert, S., Wessolly, M., Schmeller, J., Mairinger, E., Kollmeier, J., Hager, T., Mairinger, T., Herold, T., Christoph, D. C., Walter, R. F. H., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5314-0 · Cited by 40 · cited 1×
“A recent study on HR defects in a cohort of patients with mesothelioma showed both in vitro and by digital gene-expression analysis that loss of BAP1 increased sensitivity to PARP inhibitors (139).”
BackgroundPARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
Pinton, G., Manente, A. G., Murer, B., Marino, E. D., Mutti, L., & Moro, L. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12000 · Cited by 38 · cited 1×
“Several studies proposed to test the efficacy of PARP inhibitors in mesothelioma, although patients were not selected for BAP1 status (136, 137).”
BackgroundKittaneh, M., & Berkelhammer, C. H. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1559-7 · Cited by 38
Metabolic therapies inhibit tumor growth in vivo and in silico
Moreira, J. D. V., Hamraz, M., Abolhassani, M., Schwartz, L. H., Jolicœur, M., & Pérès, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-39109-1 · Cited by 37 · cited 1×
“For example, the role of metformin, a drug that reprograms cell metabolism by restraining aerobic glycolysis and promoting mitochondrial respiration (149), could be explored in the existing mouse models carrying heterozygous Bap1 mutations and in xenografts of BAP1-mutated tumors.”
BackgroundAoude, L. G., Gartside, M. G., Johansson, P. A., Palmer, J. M., Symmons, J., Martin, N. G., Montgomery, G. W., & Hayward, N. K. (2015) · Twin Research and Human Genetics · doi:10.1017/thg.2015.12 · Cited by 35
Eckel‐Passow, J. E., Serie, D., Cheville, J. C., Ho, T. H., Kapur, P., Brugarolas, J., Thompson, R. H., Leibovich, B. C., Kwon, E. D., Joseph, R. W., et al. (2017) · BMC Urology · doi:10.1186/s12894-017-0209-3 · Cited by 35
Chromosomal rearrangements and their neoantigenic potential in mesothelioma
Mansfield, A. S., Peikert, T., & Vasmatzis, G. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.12 · Cited by 35 · cited 2×
“Moreover, based on the structural rearrangements induced by chromothripsis, which may be favored by BAP1 mutations (79), Mansfield and colleagues predicted and validated in vitro the expression of altered peptides that may act as neoantigens and thus potentially increase mesothelioma immunogenicity and responsiveness…”
BackgroundWhole-genome sequencing of human malignant mesothelioma tumours and cell lines
Oey, H., Daniels, M. G., Relan, V., Chee, T. M., Davidson, M. R., Yang, I. A., Ellis, J. J., Fong, K. M., Krause, L., & Bowman, R. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz066 · Cited by 32 · cited 4×
“In addition to BAP1-mutated cancers, these studies are relevant to all human malignancies where mutations are assessed by tNGS or WES, as these techniques underestimate the extent of genetic damage.”
BackgroundInfluentialA novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer
McDonnell, K., Gallanis, G. T., Heller, K. A., Melas, M., Idos, G., Culver, J. O., Martin, S.-E., Peng, D., & Gruber, S. B. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.12.007 · Cited by 30
Okonska, A., Bühler, S., Rao, V., Ronner, M., Blijlevens, M., van der Meulen‐Muileman, I. H., de Menezes, R. X., Wipplinger, M., Oehl, K., Smit, E. F., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0356 · Cited by 29 · cited 2×
“Upon treatment with this agent or with hydroxyurea, the viability of mesothelioma spheroids expressing nonfunctional C91A BAP1 was significantly higher compared with wild-type BAP1 counterparts (127).”
BackgroundResultMesothelioma developing in carriers of inherited genetic mutations
Yoshikawa, Y., Emi, M., Nakano, T., & Gaudino, G. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.15 · Cited by 28
Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome
de la Fouchardière, A., Cabaret, O., Pètre, J., Aydın, S., Leroy, A., Potter, P. D., Pissaloux, D., Haddad, V., Paillerets, B. B., & Janin, N. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1423-2 · Cited by 27
BAP1germline mutation in two first grade family members with uveal melanoma
Maerker, D., Zeschnigk, M., Schillinger, J., Lohmann, D. R., Worm, K., Bosserhoff, A., Krupar, R., & Jägle, H. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303814 · Cited by 26
Publisher Correction: The machineries, regulation and cellular functions of mitochondrial calcium
Giorgi, C., Marchi, S., & Pinton, P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0066-2 · Cited by 26 · cited 2×
“The increase in mitochondrial Ca2+ concentration triggers the release of cytochrome c that in turn activates apoptosis (33).”
BackgroundWoodard, G. A., & Jablons, D. M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.08 · Cited by 26
Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations
Yavuzyiğitoğlu, S., Mensink, H. W., Smit, K. N., Vaarwater, J., Verdijk, R. M., Beverloo, B. H. B., Brüggenwirth, H. T., van Marion, R., Dubbink, H. J., Paridaens, D. A., et al. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18608 · Cited by 20 · cited 1×
“This figure represents a synopsis of published data (68, 101, 178).”
MethodGenomic evolution of uveal melanoma arising in ocular melanocytosisPreprint
Durante, M. A., Field, M. G., Sanchez, M. I., Covington, K. R., Decatur, C. L., Dubovy, S. R., & Harbour, J. W. (2019) · Molecular Case Studies · doi:10.1101/mcs.a004051 · Cited by 20 · cited 1×
“Because BAP1-mutant uveal melanoma does not show strong evidence of DNA damage repair defects or increased mutation burden (148), further work is needed to determine which of the possible functions of BAP1 are relevant to each cancer type in which it is mutated.”
BackgroundGenomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma
Togo, Y., Yoshikawa, Y., Suzuki, T., Nakano, Y., Kanematsu, A., Zozumi, M., NOJIMA, M., Hirota, S., Yamamoto, S., & Hashimoto-Tamaoki, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3395 · Cited by 19 · cited 1×
“The role of BAP1 as a two-hit tumor suppressor gene is underscored by the fact that in humans they are accompanied by monoallelic loss of 3p, or by biallelic deletions of the BAP1 locus (LOH), including broad deletions of 3p21, narrow deletions of several exons, or loss of the entire BAP1 allele (75, 76).”
BackgroundRavanpay, A. C., Barkley, A. S., White-Dzuro, G. A., Cimino, P. J., Gonzalez‐Cuyar, L. F., Lockwood, C. M., Halasz, L. M., Hisama, F. M., & Ferreira, M. L. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.06.227 · Cited by 18
Onder, S. C., Özoğul, E., Köksal, D., Ulaşlı, S. S., Fırat, P., & Emri, S. (2019) · Cytopathology · doi:10.1111/cyt.12738 · Cited by 18
Head and neck reconstruction using microsurgery: a 9-year retrospective study
Holom, G. H., Seland, H., Strandenes, E., Liavaag, P. G., Lybak, S., Løes, S., Tornes, K., & Vintertun, H. N. (2013) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-013-2390-7 · Cited by 17
Lin, M., Zhang, L., Hildebrandt, M. A. T., Huang, M., Wu, X., & Ye, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20465 · Cited by 16
Disselhorst, M., & Baas, P. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.16 · Cited by 16
Germline BAP1 mutations misreported as somatic based on tumor-only testing
Abdel‐Rahman, M. H., Rai, K., Pilarski, R., Davidorf, F. H., & Cebulla, C. M. (2016) · Familial Cancer · doi:10.1007/s10689-016-9865-9 · Cited by 15
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Nassar, A. H., Hamieh, L., Gray, K. P., Thorner, A. R., Fay, A. P., Lasseter, K. D., Alaiwi, S. A., Nuzzo, P. V., Flippot, R., Krajewski, K. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0642 · Cited by 14 · cited 1×
“In addition, a large study in more than 100 cases of metastatic RCC demonstrated that BAP1 mutational status did not correlate with clinical benefit upon rapalog therapy (130), despite the significantly higher aggressiveness of RCC in carriers of BAP1 mutations (131).”
BackgroundWebster, J. D., Pham, T. H., Wu, X., Hughes, N. W., Li, Z., Tótpál, K., Lee, H., Calses, P. C., Chaurushiya, M. S., Stawiski, E. W., et al. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12735 · Cited by 13 · cited 1×
“This combined therapy is the standard of care for BRAFV600E-mutant human melanoma (129).”
BackgroundHistopathology of melanocytic lesions in a family with an inherited BAP1 mutation
O'Shea, S. J., Mitra, A., Graham, J. L., Charlton, R. S., Adlard, J., Merchant, W., & Newton‐Bishop, J. (2015) · Journal of Cutaneous Pathology · doi:10.1111/cup.12625 · Cited by 12
Miura, Y., Inoshita, N., Ikeda, M., Miyama, Y., Oki, R., Oka, S., Kondoh, C. N., Ozaki, Y., Tanabe, Y., Kurosawa, K., et al. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.02.003 · Cited by 12 · cited 2×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundEmi, M., Yoshikawa, Y., Sato, C., Sato, A., Sato, H., Kato, T., Tsujimura, T., Hasegawa, S., Nakano, T., & Hashimoto-Tamaoki, T. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.91 · Cited by 10 · cited 1×
“The role of BAP1 as a two-hit tumor suppressor gene is underscored by the fact that in humans they are accompanied by monoallelic loss of 3p, or by biallelic deletions of the BAP1 locus (LOH), including broad deletions of 3p21, narrow deletions of several exons, or loss of the entire BAP1 allele (75, 76).”
BackgroundOka, S., Inoshita, N., Miura, Y., Oki, R., Miyama, Y., Nagamoto, S., Ogawa, K., Sakaguchi, K., Kondoh, C. N., Kurosawa, K., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.04.015 · Cited by 9 · cited 2×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundLoss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations
Maffeis, V., Cappellesso, R., Nicolè, L., Guzzardo, V., Menin, C., Elefanti, L., Schiavi, F., Guido, M., & Fassina, A. (2019) · Endocrine Pathology · doi:10.1007/s12022-019-09595-0 · Cited by 9
Bochtler, T., Endris, V., Reiling, A., Leichsenring, J., Schweiger, M. R., Klein, S., Stögbauer, F., Goeppert, B. F., Schirmacher, P., Krämer, A., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7012 · Cited by 8
Wysozan, T. R., Khelifa, S., Turchan, K., & Alomari, A. K. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13525 · Cited by 7
GROWTH OF PRESUMED CHOROIDAL NEVUS INTO MELANOMA OVER 4 YEARS IN BAP1 TUMOR PREDISPOSITION SYNDROME
Masoomian, B., Shields, C. L., Mashayekhi, A., Ganguly, A. A., & Shields, J. A. (2018) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000772 · Cited by 5
Watchorn, R. E., Calonje, E. J., & Taibjee, S. M. (2018) · Pediatric Dermatology · doi:10.1111/pde.13553 · Cited by 3
BAP1 Tumour Predisposition Syndrome: A New Mutation in One Family
Satolli, F., Giudice, M. B. D. F. D., Bertolani, M., Ricci, R., Lotti, T., Zucchi, A., & Feliciani, C. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3267 · Cited by 2
Research works printed but not linked: 1
- Carbone, 2012, Nat Rev Cancer
Cited by
Targeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
A pathology foundation model for cancer diagnosis and prognosis prediction
Wang, X., Zhao, J., Marostica, E., Yuan, W., Jin, J., Zhang, J., Li, R., Tang, H., Wang, K., Li, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07894-z · Cited by 580
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 390
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease
Nguyen, T. T., Wei, S., Nguyen, T. H., Jo, Y., Zhang, Y., Park, W., Gariani, K., Oh, C.-M., Kim, H. H., Ha, K.-T., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01046-5 · Cited by 325
Metadata
- Authors
- Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G.
- Affiliations
- University of Hawaii Cancer Center (US)
- University of Miami (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Genentech (US)
- University of Chicago (US)
- NYU Langone Health (US)
- Corresponding author
- Carbone, Michele
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1103-1120
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8006752
- OpenAlex
- W3042684909
- Cited by
- 287
- References
- 179
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 61 · 2023: 51 · 2022: 48 · 2021: 36 · 2020: 4
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIEHS (1R01ES030948-01)
- NCI (1R01CA237235-01A1, 1R01CA198138, U01CA111295-08)
- U.S. Department of Defense (CA150671)
- Department of Defense (W81XWH-15-1-0578)
- NIH (R01 CA125970, P30CA240139, P30EY014801, 1P50CA196516, R01CA175754, RP180192)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- BAP1, BAP1 mutation, tumor suppressor, uveal melanoma, cutaneous melanoma, mesothelioma, clear cell renal cell carcinoma, germline mutations, somatic mutations, DNA repair, transcription, cell death, mitochondrial metabolism, gene-environment interaction
- MeSH terms
- Humans, Kidney Neoplasms, Melanoma, Mutation, Skin Neoplasms, Uveal Neoplasms, Tumor Suppressor Proteins, Ubiquitin Thiolesterase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.